Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company based in Jerusalem, Israel, operating in Israel and internationally. It researches and develops IL-17 NanoAb, a VHH-based antibody platform for immune-mediated and inflammatory diseases including psoriasis, and PC111, a human monoclonal antibody for pemphigus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Göttingen for NanoAb candidates, and with Recipharm Israel Ltd for biologics and small-molecule programs. Formerly known as BiondVax Pharmaceuticals Ltd., it changed its name to Scinai Immunotherapeutics Ltd. in September 2023 and was incorporated in 2003.